US Stock MarketDetailed Quotes
ADXS Ayala Pharmaceuticals
- 0.621000
- -0.047000-7.04%
15min DelayClose Apr 15 16:00 ET
26.48MMarket Cap-247P/E (TTM)
0.668000High0.607000Low6.11KVolume0.668000Open0.668000Pre Close3.78KTurnover0.06%Turnover RatioLossP/E (Static)42.63MShares1.95000052wk High-4.25P/B5.97MFloat Cap0.51120052wk Low--Dividend TTM9.61MShs Float187499.985000Historical High--Div YieldTTM9.13%Amplitude0.511200Historical Low0.618000Avg Price1Lot Size
About Ayala Pharmaceuticals Company
Ayala Pharmaceuticals, Inc. is a clinical-stage oncology company, which engages in developing and commercializing small molecule therapeutics for patients suffering from rare tumors and aggressive cancers. Its lead candidates are the oral gamma secretase inhibitor, AL102, for desmoid tumors, and aspacytarabine (BST-236), a novel proprietary anti-metabolite for first line treatment in unfit acute myeloid leukemia. The company was founded in November 2017 and is headquartered in Monmouth Junction, NJ.
Company Profile
SymbolADXS
Company NameAyala Pharmaceuticals
Founded2017
CEOMr. Kenneth A. Berlin
MarketPink Market
Employees35
Securities TypeOrdinary Shares
Fiscal Year Ends12-31
Address9 Deer Park Drive,Suite K-1
CityMonmouth Junction
ProvinceNew Jersey
CountryUnited States of America
Zip Code08852
Phone1-609-452-9813
Websitehttp://www.ayalapharma.com
Company Executives
- Name
- Position
- Salary
- Anthony A. Lombardo
- Interim Chief Executive Officer
- --
- Kenneth A. Berlin
- Director, President and Chief Executive Officer
- --
- Dr. Andrew A. Gutierrez, M.D.
- Chief Medical Officer
- --
- Sara Bonstein
- Chief Financial Officer, Executive Vice President and Corporate Secretary
- --
- Robert Petit, PhD
- Chief Scientific Officer and Executive Vice President
- 1.94M
- Igor Gitelman
- Chief Financial Officer
- --
- Dr. James Patton
- Vice Chairman of the Board
- 264.00K
- Roni A. Appel
- Independent Director
- 216.50K
- Dr. Thomas Mckearn, PhD
- Independent Director
- 221.50K
- The Honourable Tom Ridge
- Independent Director
- 215.25K
- Richard J. Berman
- Independent Director
- 231.00K
- Dr. Samir N. Khleif
- Independent Director
- 226.50K
Analysis
Price Target
No Data
Heat List
US
Overall
Symbol
Latest Price
%Chg